Bioaccessibility and Bioavailability of ACE Inhibitory Peptides from Fermented Milk with <i>Lactococcus lactis</i> NRRL B-50571 after an Ex Vivo Absorption Model
Miguel A. Álvarez-Olguín, Aarón F. González‐Córdova, Adrián Hernández‐Mendoza, Lilia M. Beltrán‐Barrientos, Rogerio R. Sotelo‐Mundo, María J. Torres‐Llanez, Belinda Vallejo‐Córdoba
Abstract
The present study aimed to determine the bioaccessibility and bioavailability of peptide fractions with angiotensin-converting enzyme inhibition (ACEI) from fermented milk with Lactococcus lactis NRRL B-50571 (FM-571) after being subjected to simulated gastrointestinal digestion (SGD) and an ex vivo absorption model. Results showed that ACEI increased ( p < 0.05) after SGD and decreased ( p < 0.05) after absorption. Conversely, the IC 50 decreased ( p < 0.05) after SGD and after absorption. Moreover, peptide abundance increased ( p < 0.05) after SGD, indicating augmented bioaccessibility. Thereafter, peptide abundance decreased ( p < 0.05) after absorption, resulting in 1.36 ± 0.1% of peptide bioavailability. Furthermore, RP-HPLC collected fractions from the serosal compartment exhibited the lowest IC 50 . 113 peptides were identified in the serosal compartment, from which 14 bioavailable peptides showed high binding potential to ACE after in silico analysis. Henceforth, these results suggest that novel peptides derived from FM-571 with ACEI were bioavailable.